The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
The aim of this study is to develop a large, ethically sourced, and diverse database of voice recordings to determine whether voice has biomarkers for particular disease categories, including neurological and neurodegenerative conditions. The data that is collected will be used to develop a full open-access database to fuel artificial intelligence research related to voice.
- Are between the ages of 44-85
- Are able to read, write, speak, and understand English
- Are diagnosed with one of the following conditions:
- Consent to provide a voice/speech sample
This study examines how people with dementia or MCI perform household tasks, focusing on when they seek support, and which prompts help them complete tasks. The findings will help develop technologies to assist them in completing tasks more independently and safely.
You are eligible to participate if you are:
• An older adult aged 60-85
• Fluent in English
• Diagnosed with dementia or MCI
• Enrolled in outpatient care
The uOttawa Sleep Laboratory is looking for adults to participate in a research study investigating the relationship between sleep and memory. Brain activity will be recorded using functional electroencephalography (EEG).
To be included participants must be:
- Right-handed
- Native English speakers
- No psychiatric disorders (past or present)
- Healthy adults, or those with memory complaints, or those with mild cognitive impairment
McMaster University, in partnership with Ressam Gardens Memory Care Community, is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a non-invasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.
You are eligible to participate if you…
1.) Diagnosed with Dementia and/or memory loss by a clinician
2.) Exhibit adequate oral communication skills and cognitive function sufficient to obtain a score ranging between 10-27 on the Mini-Mental State Exam
3.) Walk or stand with or without personnel or assistive devices
4.) Individuals must be greater than or equal to 50 years of age
This study will uncover how bilingualism supports healthy cognitive aging by examining the influence of different language experiences on the timing and location of brain network activity. We will examine the timing of brain activity using electroencephalography (EEG; i.e., recordings of electrical brain activity) and the location of brain activity using magnetic resonance imaging (MRI; i.e., images of activity in different parts of the brain). Different language experience factors will additionally be explored. By measuring multiple factors (e.g., the age of second language learning, language proficiency) the effect(s) of different language experiences on the brain and cognition will become clearer.
You are eligible to participate if you:
- are a French-English bilingual over the age of 65
- have mild cognitive impairment
- have Alzheimer's disease
- are a healthy older adult (i.e., have no cognitive conditions)
Please note that you do not need to be completely fluent in both English and French, just to have some familiarity, experience or training with both languages to be eligible to participate.
Thank you for your consideration!
Early detection of brain changes is crucial to prevent cognitive decline and dementia. This study uses electroencephalography (EEG) to record the brain's electrical signals during simple tasks, with the hope of validating a measure that can improve early detection of Alzheimer’s disease.
We are recruiting 150 individuals with mild memory issues and mild dementia at Baycrest in Toronto and Bruyère in Ottawa. In a separate study we are also recruiting older adults with no memory problems. The results of both studies together will help us determine if our new EEG measure can detect abnormal changes in brain health early on and if it can help predict future cognitive changes. We hope that this new test will be used in the clinic to identify individuals who may benefit the most from early treatment and interventions.
- Are between 60 and 85 years of age
- Have a diagnosis of amnestic mild cognitive impairment or mild dementia due to Alzheimer’s
- Have normal vision (with visual aids, if needed) and no other serious health issues
- Ability to speak English
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
60+
Diagnosis of Alzheimer's disease
Must have a study partner
It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.
You are eligible to participate if you meet the following criteria:
• Age ≥ 55; females must be post-menopausal
• DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)
• sMMSE ≤ 24
• Clinically significant agitation based on IPA definition
• Stable cognition-enhancing medication for at least 3 months prior to study enrolment
• Availability of a caregiver to accompany participant to study visits and to participate in the study
• Ability to speak English
Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.
Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.
Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.
Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.
Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.
Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.
Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.
Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.
Have not undergone any significant head trauma or surgery in the past 6 months.
Are not pregnant or planning to become pregnant during the duration of the study.
Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.
Ability to speak English and French
Follow us: